BACKGROUND: The American College of Surgeons Oncology Group Z0011 trial results provided convincing evidence that completion axillary lymph node dissection (CALND) was unnecessary in selected patients with 1 to 2 positive sentinel lymph nodes (SLNs). We hypothesized that preoperative axillary ultrasound (AUS) with fine-needle aspiration is sufficiently sensitive to detect worrisome macrometastasis to preclude the need for frozen-section pathology of SLNs. STUDY DESIGN: We conducted a retrospective single-institution study at a tertiary academic referral center.
Nearly 120 years ago, the outlook for patients with breast cancer was bleak, summarized by Halsted's admission that "most of us have heard our teachers in surgery admit that they have never cured a case of cancer of the breast." 1 Fast forward to recent publications of the randomized trial, American College of Surgeons Oncology Group (ACOSOG) Z0011, 2, 3 in contrast to the extensive resection of the Halsted radical mastectomy, the ACOSOG Z0011 study provides a strong basis to limit surgical intervention to wide local excision and sentinel lymph node (SLN) biopsy only in many patients, even if the SLNs contain metastatic deposits. Specifically, with a mean follow-up of 6.3 years in breast cancer patients with T1 to 2 cancers without preoperative palpable lymphadenopathy and who are treated with breastconservation surgery followed by usual breast radiotherapy and standard adjuvant medication, there was no benefit to completion axillary lymph node dissection (CALND) beyond SLN biopsy alone for patients with 1 or 2 positive SLNs with respect to disease-free survival, overall survival (OS), or overall local recurrence. In addition, the axillary recurrence rate in patients who had only the positive SLN(s) removed was just 0.9%. Some bias in patient enrollment in the study was inevitable, and technology has progressed since the study was initiated. Patients enrolled had "favorable" disease, notably 70% had T1 tumors, 83% were estrogen receptor (ER)Àpositive, 71% had a single SLN positive and 44% had only micrometastases, 38% were 50 years or younger, and only 27% of those patients undergoing CALND had additional positive lymph nodes (compared with a 53% positive rate in meta-analysis of >8,000 patients 4 ).
From 2007, axillary ultrasound (AUS) with percutaneous fine-needle aspiration (FNA) of morphologically abnormal lymph nodes has been used at Mayo Clinic in Rochester to identify the subset of patients with cytology-detected metastatic lymph nodes to avoid the time and expense of SLN mapping, SLN biopsy, and frozen section. With the enhancement of AUS with or without FNA to physical examination, we treat these patients as LN positive, and ALND has been incorporated into their operative management. The ACOSOG Z0011 trial did not use preoperative AUS in the workup of patients.
After publication of the ACOSOG Z0011 trials results, we hypothesized that preoperative AUS was sufficiently sensitive to detect breast cancer with SLN disease that would warrant axillary dissection to preclude the need for intraoperative frozen-section pathologic review for the remainder of patients with negative AUS who were undergoing SLN surgery. The aim of this study was to determine the frequency and size of macrometastases, and the number of patients with !3 positive SLNs, especially in the higher-risk, ER-negative, and premenopausal patients. Ultimately, we intended to identify which breast cancer patients AUS with or without FNA was sufficiently sensitive for to eliminate the attendant time and cost of intraoperative frozen-section histology of SLNs removed in breast-conservation surgery.
METHODS

Study design and data collection
The single-center, retrospective study included clinical T1 and T2 breast cancer patients who underwent SLN biopsy with or without CALND from January 1, 2007 to December 31, 2010. Data were collected from 2 prospective databases maintained at the Mayo Clinic in Rochester: Cancer Registry (2007e2008) and Breast Surgery Database (2009Àonward). Medical records were reviewed for patient demographics; year of surgery; clinical history; imaging; primary tumor histology; grade; stage; hormone status; human epidermal growth factor receptor-2/neu status; results of AUS and FNA, if performed; number of sentinel nodes retrieved; number of positive nodes by histologic examination; outcomes of axillary dissection (if conducted); and size of the largest metastatic lymph node deposit (if node positive). Axillary ultrasound became institutional practice for all patients with a diagnosis of invasive breast carcinoma at the end of 2006, and we incorporated records from 2007 onward. Only patients who had clinically node-negative breast cancer, preoperative negative AUS, or suspicious lymph nodes on AUS, but were FNA cytologyÀnegative, performed at Mayo Clinic in Rochester, and had SLN biopsy were included. All participants were women at least 18 years of age with clinical T1 or T2 N0 M0 breast cancer treated with SLN biopsy and either breastconserving surgery or mastectomy. Only patients who were candidates for breast conservation but elected mastectomy were included. Patients treated with neoadjuvant chemo-or hormonal therapy, palpable and grossly involved adenopathy, T3 or T4 tumors, multicentric disease, preoperatively established metastases by AUS and positive FNA cytology, or with previous axillary surgery, were excluded from this study. This study has been approved by the Institutional Review Board of the Mayo Clinic.
Axillary ultrasonography and sentinel lymph node biopsy All AUS was performed by dedicated breast ultrasonographers using high-resolution linear-array transducers with a maximum frequency of at least 12 MHz, with scanning in transverse and sagittal planes. Lymph nodes with hilar effacement, hilar replacement, node matting, perinodal edema, and unclear node margins and cortical thickening >3 mm, especially if nodular or asymmetric on AUS, were considered abnormal. All suspicious lymph nodes were followed up by FNA biopsy performed with local anesthesia; a 25-gauge needle was used to obtain specimens for cytologic examination. Cases with positive FNA cytology were excluded from this analysis. Sentinel lymph nodes were identified using radioactive colloid and/or blue dye according to the surgeon's preference. Intraoperative frozen section and permanent hematoxylin and eosin staining were performed on all SLNs. Immunohistochemical staining was performed on all SLNs that were negative by frozen-section examination and permanent hematoxylin and eosin. Sentinel lymph nodes were considered positive if metastasis seen by immunohistochemical or hematoxylin and eosin stains measured >0.2 mm. Isolated tumor cells were classified as negative for metastases as per the American Joint Committee on Cancer 7 th edition staging guidelines.
Study end points and reference standards
The primary end point was the pathology result from SLN biopsy as determined by frozen section and permanent pathology analysis. The study plan was to compare pathology results after SLN biopsy with preoperative AUS with or without FNA to determine the sensitivity of AUS with or without FNA as a tool to eliminate the need for frozen section in patients meeting ACOSOG Z0011 criteria.
The size of the largest metastatic deposit was used to categorize lymph nodes as isolated tumor cells (<0.2 mm), micrometastases (0.2 to 2 mm), or macrometastases (>2 mm).
Statistical analysis
Frequency distributions and univariate analysis were used to summarize and compare patient characteristics. Chisquare test, independent samples t-test, and logistic regression were used to compare effects of clinical characteristics and the correlation of outcomes from AUS with or without FNA and SLN biopsy pathology. All analyses used a 2-tailed significance level of 0.05 and were performed using SPSS version 19 (SPSS, Inc).
RESULTS
A total of 1,140 patients with negative AUS with or without FNA were included in our study and Figure 1 shows a flow diagram of the patient-selection process. Positive nodes were found in 144 (12.6%) patients and 996 had negative SLNs. Patient demographics and tumor characteristics are shown in Table 1 . There were 822 patients (72%) with invasive ductal carcinoma, 120 patients (11%) with invasive lobular carcinoma, 110 patients (10%) with mixed invasive ductal and lobular carcinoma, and 43 patients (4%) with other histologic types. There were 817 patients (71%) with T1 stage. Mean age on presentation was 62 years. The majority of patients were ER positive (71%) and progesterone receptor positive (63%). Human epidermal growth factor receptorÀ2 status was significantly different between the SLN-positive and SLN-negative patients (human epidermal growth factor receptorÀ2 negative 88% vs 30%; p < 0.0001, respectively). Two hundred and sixteen patients (19%) had abnormal lymph nodes on AUS and went on to ultrasound-directed FNA, which was negative for metastatic disease, and the lymph nodes were deemed negative by ultrasound in 924 patients (81%). The mean number of SLNs excised in the node-positive group was not significantly different from the node-negative group (2.69 vs 2.62; p ¼ 0.57). The correlation of AUS with or without FNA with the pathology results after SLN biopsy is summarized in Figure 2 . In our study, 87.4% of preoperative negative AUS with or without FNA were truly negative. Table 2 shows a comparison of the node-positive patients in this study with the patients enrolled in ACOSOG Z0011. Of the 144 node-positive patients in this study, micrometastases were found in higher frequency (49% [70 patients]) than in the ACOSOG Z0011 study. Of the 144 patients with positive SLNs, 100 underwent CALND, 27 of them had additional non-SLNs with metastasis, which is similar to the (20) BCS, breast-conserving surgery; ER, estrogen receptor; FNA, fine-needle aspiration; Her-2, human epidermal growth factor receptor; PR, progesterone receptor.
findings in ACOSOG Z0011. Only 4 (3%) patients had !3 SLNs positive and, retrospectively, would have required CALND by the subsequently published ACO-SOG Z0011 findings. Compared with the ACOSOG Z0011 study, this node-positive group had fewer patients who were premenopausal (25%), ER negative (9%), and progesterone receptor negative (18%) than the ACOSOG Z0011 study groups. Only 10 patients demonstrated macrometastases >7 mm, and 19 patients with macrometastases of !6 mm ( Table 3 ). In patients with !6 mm SLN metastasis, only a single patient had !3 positive SLNs on pathology. To determine whether patients with a positive SLN were similar in terms of disease burden to patients with negative SLN, they were compared with respect to age, tumor grade, histology, size, American Joint Committee on Cancer stage, hormone and menopausal status, and type of surgery ( Table 1 ). The SLN-positive group had a higher proportion of premenopausal women (28% vs 20%; p < 0.0001) and higher number of initially suspicious lymph nodes on preoperative AUS deemed negative by FNA (29% vs 17%; p ¼ 0.001) as compared with SLN-negative group.
DISCUSSION
The key message from this study is that for patients who fulfill the ACOSOG Z0011 study criteria, the addition of a negative preoperative AUS with or without FNA should reduce the risk of SLN macrometastases of !6 mm to just 2% and >7 mm to 1%. Similarly, such SLN macrometastases in potentially high-risk premenopausal or ER-negative patients would be found in only a fraction of 1%, and only 3% of patients had !3 positive SLNs. Additional residual non-SLNs would be found in only about 0.5% of patients. We recognize that, going forward, a positive preoperative ultrasound-FNA currently commits about 10% of our patients to axillary dissection, at least some of whom can be adequately treated with whole-breast radiation, sentinel node biopsy, and adjuvant therapy only. The impact on survival of metastatic axillary LNs has been questioned for more than 35 years. The National Surgical Adjuvant Breast Project B-04 study, predating the publication of the ACOSOG Z0011 study by 25 years, and actually initiated in 1971, reported 10-year results including >1,700 patients randomized to either radical mastectomy, total mastectomy with axillary radiation (instead of axillary lymphadenectomy), or total mastectomy alone with subsequent axillary lymphadenectomy for development of clinically evident axillary lymph node metastasis (without any adjuvant therapy). 5 There were no differences in disease-free survival or OS, which remained true after 25 years of follow-up. 6 These data raised serious question about the survival impact of either surgically removing or irradiating occult-positive axillary nodes in breast cancer. But the value of knowing the disease status of the lymph nodes has remained paramount in disease staging and been a key decision point for the use of adjuvant therapy.
In 1997, however, randomized studies demonstrated marked improvement in not only local recurrence, but also in disease-free survival and OS in post-modified radical mastectomy, axillary nodeÀpositive patients given postoperative adjuvant radiotherapy in addition to standard chemotherapy. [7] [8] [9] Therefore, the need for and value of axillary dissection, and perhaps radiation for nodepositive disease, seemed solidly established.
Almost synchronously, Giuliano and colleagues 10 published their early experience of intraoperative lymphatic mapping and axillary SLN biopsies. This technique evolved and eventually seemed ideal to meet the need for precise axillary lymph node disease staging that avoided unnecessary axillary node dissection for node-negative disease, and reduced the attendant surgical morbidity. Careful surgical/pathologic correlation revealed that in only about 50% of patients with metastatically involved SLNs were non-SLNs involved. Contrary to the Fisher hypothesis, 11 there might actually be some barrier function to SLN, as survival was better if only SLNs were positive compared with patients with both SLN and non-SLN involvement. 12 Surgeons and oncologists have struggled with the best method to limit axillary dissection to just those with high enough risk of additional non-SLNs to justify CALND when the SLN contained this limited disease. Mathematical models to predict non-SLN involvement when the SLN is positive have been devised [13] [14] [15] to facilitate decisions whether to recommend CALND. Implicit in this decision, however, is the recognition that some patients who choose to forego reoperation will actually have residual positive non-SLN.
Clearly, there has been a trend to forego CALND even when the SLN is positive, especially when the disease is limited to micrometastasis. Review of the Surveillance, Epidemiology, and End Results database in 2010 revealed that 40% of patients with SLN micrometastases did not undergo CALND. 16 Additional analysis of the Surveillance, Epidemiology, and End Results database, reviewing nearly 27,000 patients with positive nodes, demonstrated that >16% had undergone SLN biopsy only, and the remainder had proceeded to CALND. 17 Impressively, there was no statistically significant difference in OS between the SLN biopsy only and the CALND groups. Similarly, Bilimoria and colleagues 18 reviewed the National Cancer Data Base from 1999 to 2005, comprising nearly 100,000 node-positive patients, about 20% of whom had SLN biopsy only, and the remaining 80% had CALND. In patients with only microscopic nodal metastasis, there was no difference in axillary recurrence or survival between the 2 groups, and in macroscopic nodal disease, a nonsignificant trend was found for the CALND group compared with the SLN biopsyonly patients.
Publication of the ACOSOG Z0011 trial solidified the evolving data-driven practice that CALND could be safely avoided in patients with T1 to 2 tumors, who were clinically node negative, with 1 to 2 positive SLNs, who had undergone breast-conservation therapy, and who would be treated with standard breast radiation and adjuvant therapy.
The response to the study was rapid and bold. For breast-conservation patients, the Memorial Sloan-Kettering Cancer Center Breast Service eliminated intraoperative frozen section as well as CALND in patients with 1 to 2 positive SLNs, regardless of metastasis size. 19 Similarly, the multidisciplinary group at the University of Texas MD Anderson Cancer Center endorsed avoidance of CALND for patients who fulfill the ACOSOG Z0011 study criteria. Additionally, routine intraoperative SLN assessment is no longer performed for these patients. However, the radiation oncologists at MD Anderson Cancer Center intend to modify the opposing tangential whole-breast radiation fields for women who do not undergo CALND. In contrast to usual breast radiation required in the ACOSOG Z0011 trial, high tangents will be added, increasing the coverage to >80% of axillary levels I and II.
Amid the strong endorsement of the ACOSOG Z0011 study results and recommendations, concern has been raised that the highly favorable results might not be achieved when applied to the usual cross-section of breast cancer patients and that the ACOSOG Z0011 study was a highly selected patient group. Under-represented were cancers generally regarded as more virulent and with greater disease burden. These would include a much higher percentage of lymph node macrometastasis and ER-negative and premenopausal females.
To counteract these, clinicians derive some confidence in potentially leaving microscopic disease in residual lymph nodes by the therapeutic effect of adjuvant therapy. The After Mapping of the Axilla: Radiotherapy or Surgery? (AMAROS) phase III study compares axillary lymph node dissection and axillary radiation therapy in early breast cancer with tumor-positive SLNs. Although the principal results of the study have yet to be published, the influence of random assignment to CALND or axillary radiation therapy on the choice of adjuvant treatment has been analyzed. 20 Importantly, the absence of knowledge about the extent of nodal involvement in the axillary radiation therapy arm did not have a major impact on the administration of adjuvant therapy. In addition, adjuvant therapy is progressively being advised on the basis of tumor biology rather than number of histologically positive nodes. Radiation oncologists, however, seem concerned that the therapeutic effect on levels I and II from radiation limited to whole-breast fields might be inadequate. 21 Using standard tangential fields, >50% of level I and 20% to 30% of level II nodes receive 95% of the prescribed radiation dose, the use of additional high tangential fields has been shown to include the majority of level I to II nodes. 22 Adjusting the radiotherapy fields has been proposed based on as many as 9 factors: breast cancer histology, tumor size, ER status, presence of lymphovascular invasion, multifocality, number and size of SLN metastasis, and total number and presence of extranodal extension of positive SLNs. 22 Support for this position derives from the Early Breast Cancer Trialists' Collaborative Group's conclusion that during a 15-year period, avoidance of local recurrence in 4 patients would avoid 1 breast cancer death. 23 Additionally, the recent MA-20 trial has added additional evidence to earlier studies 7-9 that found survival and local recurrence benefits in patients with metastatic lymph nodes when regional nodal irradiation was added to whole-breast radiation. 24 Stunningly contrary to the complex adjustments proposed by the radiation oncologists, several upcoming clinical trials are being proposed to evaluate whether SLN staging overall can be abandoned. In Europe, Gentilini and Veronesi have proposed a new clinical trial: Sentinel Node vs Observation after Axillary Ultrasound (SOUND). The premise for this study is that not only is wider surgery in the axilla "not improving outcome but also that the information achieved by removing lymph nodes does not change the prognosis of the disease." Extending the thinking, they believe that because local control is excellent, survival is unchanged, presence and extent of nodal involvement does not change type of treatment, "do we even need to look for a SLN?" The SOUND study eligibility criteria would be rather similar to the ACOSOG Z0011 study: T1 tumors, clinically negative axillary nodes, and breastconservation therapy, including radiotherapy. However, they add axillary ultrasound as a means of screening for "clinically relevant nodal burden." With either a negative AUS or a negative ultrasound/FNA of any questionable node, the patient would be randomized to either SLN biopsy with or without CALND, or no axillary surgical staging at all.
Axillary ultrasound with percutaneous FNA or coreneedle biopsy of suspicious lymph nodes has been used to identify patients with positive nodes preoperatively to prevent the time, expense, and any morbidity of the SLN localization and procedure and also to guide nodal staging for consideration of neoadjuvant chemotherapy. A positive ultrasound/FNA would imply need for axillary lymphadenectomy. Criteria such as lymph node cortical thickening, asymmetry, plus the addition of ultrasound and needle sampling rather than imaging criteria alone, were intended to improve the sensitivity. 25 For nonpalpable axillary nodes, sensitivity ranges from about 44% to 73%. 26, 27 Without minimizing the importance of sensitivity, the principal emphasis of AUS, and the reason for incorporating ultrasound/FNA, was to assure virtually 100% specificity. Axillary US with or without FNA was shown to be cost effective for invasive breast cancer because of the decreasing need for SLN biopsy for nodal staging. 28 There is a new aim for AUS, or at least the aim has shifted somewhat. To be applied across the entire spectrum of breast cancer patients who fulfill the ACOSOG Z0011 eligibility criteria, not just patients with favorable disease, the sensitivity needs to be sufficient to identify nodal disease burden that would be responsible for disease relapse. The ACOSOG Z0011 study clearly demonstrates that this sensitivity requirement is well below 100%, but the exact threshold remains unknown.
The value and accuracy of frozen-section analysis of SLNs has been investigated. When integrated into an evaluation process including preoperative AUS with FNA, SLN biopsy, and intraoperative frozen section, Genta and colleagues 29 found that about 30% of the positive nodes were identified by ultrasound/FNA, an additional 30% were confirmed by frozen section, and about 35% were identified only after final definitive permanent histologic analysis. It is no surprise that the fraction of patients in our study who had positive lymph nodes with CALND was similar to the 27% seen in the ACOSOG Z0011 study, and far fewer than the 53% in the meta-analysis of 8,000 patients. Patients with larger tumors now often receive neoadjuvant therapy; patients with multicentric cancers that would require mastectomy and those with ultrasound/FNA-positive nodes were excluded from this study. We recognize that by committing patients with preoperative ultrasound/FNA-positive lymph nodes to axillary dissection might encompass some who would be managed satisfactorily with SLN biopsy alone, relying on the combined radiation and adjuvant therapy to prevent axillary LN relapse. We do not have precise break points for disease burden or markers of excessive disease virulence that might be best treated with CALND. We have gained additional confidence, however, that for small breast cancers, with no palpable lymphadenopathy or positive LNs by AUS, managed with breast-conservation therapy, including whole-breast radiation therapy and planned adjuvant treatment, that SLN metastasis !6 mm will be found in only 2% of patient, and >7 mm in only 1%. In addition, only 3% will have !3 SLNs, and it seems a very small percentage would be expected to be ER negative. Consequently, with the addition of AUS with or without FNA, we endorse the conclusions of the ACOSOG Z0011 trial to avoid CALND, and we see marginal gain in continuing frozen section of SLNs in these patients. 1 . Who performed the axillary ultrasonographic procedures at your institution? 2. How many of the patients undergoing axillary ultrasonography had a fine needle aspiration (FNA), and how many axillary lymph nodes were biopsied? 3. How many total lymph nodes were positive in the 1 patient with more than 3 lymph nodes?
DR CLIVE S GRANT: Thank you, Dr Waer, for your questions. First, at Mayo Rochester, the practice is that radiologists do the mammography, the mammographic and ultrasound-directed needle biopsies, and they also do the ultrasound. The frequency of FNA is 29%. I think that gets to be a bit arbitrary, however, because 1 radiologist might say, "Okay, the criteria are these, and I'm a little suspicious," so if they are much more suspicious, they will use ultrasound-directed FNA. And there are a fair number of those patients whose FNA turns out to be negative. So I think they have set criteria, cortical thickness, etc, but it may vary from 1 radiologist to another. And the number of lymph nodes in that 1 patient who had 3 or more was 3 lymph nodes.
DR NORA HANSEN (Chicago, IL): I congratulate the authors on an excellent presentation. I am concerned that your approach will subject more patients to a potentially unnecessary axillary lymph node dissection (ALND). In your study, for the patients who had a positive FNA based on an axillary ultrasound, how many patients had more than 2 positive nodes on an axillary dissection? As you know, in the American College of Surgeons Oncology Group (ACOSOG) Z0011 study, only patients with more than 2 positive sentinel nodes were required to undergo an axillary lymph node dissection. By proceeding directly to ALND for a positive FNA axillary node on axillary ultrasound, you may be subjecting more patients to an ALND than needed. At our institution, we have been trying to avoid axillary ultrasound unless we are clinically suspicious of positive axillary nodes on physical examination or if patients are undergoing a mastectomy. We no longer do frozen section on sentinel nodes for clinically negative lymph nodes and await the final pathology to decide whether or not the patient requires further axillary surgery. Your approach may be subjecting more patients to unnecessary ALND.
DR CLIVE S GRANT: I certainly understand what you are saying. And there are many institutions that used to do axillary ultrasound to facilitate avoiding the sentinel node biopsy when the axillary ultrasound, needle biopsy was positive. And then they would skip the sentinel node step and do an axillary dissection. Your point is, are we, in fact, committing patients to have an axillary dissection when, in fact, they might be eligible and well treated with radiation to the breast that spills over into the axilla. We have taken the tack that axillary ultrasound has become part of our clinical preoperative examination. We are balancing those patients who may have positive nodes that we sort of overtreat with axillary dissection, compared with patients about whom, if we do only examination, we would be very nervous that we might, in fact, undertreat some who might be premenopausal, estrogen receptor negative, and have bigger metastases that we didn't detect with just palpation. And we feel more comfortable using the ultrasound. So it's a balance between those two.
DR JOHN RUSSELL (Albuquerque, NM): In the presentation, you said that these were breast conservation surgery-eligible patients, but it wasn't clear whether you included any mastectomy patients in your study. If you did, and those patients had positive sentinel nodes, how did you subsequently manage the axilla in those patients?
DR CLIVE S GRANT: That was, obviously, the retrospective part. And the intent was, if you are facing patients who are going to consider breast conservation vs mastectomy, if they were breast conserving surgery-eligible based on size and extent, even if they had a mastectomy, which was a bit arbitrary in some of the criteria, we included them because we wanted to use a wider population than if we narrowed it to maybe just those breast-conserving therapy patients. So we did include mastectomy patients, but their assessment would have allowed them potentially to be breast conserving surgery-possibility patients. And back then, we were doing completion axillary dissection for anything that was positive. It's from this point forward that we are really talking about avoiding axillary dissection for potentially sentinel node-positive patients, but only in the breast-conserving surgery group right now. There are no prospective data, randomized data that allow you to avoid an axillary dissection if you have a positive sentinel node and you are already planning a mastectomy. That can be an awkward discussion at times.
DR DAVID WINCHESTER (Evanston, IL): I just wanted to echo some of Dr Hansen's comments. If you look at the reports that were in some of your opening slides, the SEER data, the National Cancer Data Base data, the Z0011, they all point to a 1% recurrence rate and no difference in survival. As you look at these reports, there's no difference in survival for patients who do and do not have axillary dissections. We are moving away from doing more aggressive lymph node surgery. How do you incorporate this algorithm into practice if we are seeing that there is no difference in survival or regional recurrence with axillary dissection, especially in an era of increased use of adjuvant therapy?
DR CLIVE S GRANT: What we have done is used axillary ultrasound as one of our preoperative clinically relevant decisionmakers about doing a completion axillary dissection at this point.
There is a study proposed, which I think is very interesting, which would look at patients who meet the Z0011 criteria, that is, tumor size 2 cm or smaller, who by axillary ultrasound, have negative nodes. Those patients would be randomized to doing sentinel node vs doing no axillary investigation, that is, no axillary sentinel node, because if it doesn't change their outcome, if the recurrence is low, and, in fact, if the adjuvant therapy is not being changed by the nodes being positive or a number of nodes being positive, the importance of axillary nodes is diminished. Right now, we do use ultrasound to help us decide about who needs a completion axillary dissection for breast conservation patients.
